Woodline Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Woodline Partners’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$74.1M	Buy	246,282 +2,399	+1%	+$724K	0.23%	106
2026 Q1	$80.7M	Buy	243,883 +242,124	+13,765%	+$82.4M	0.31%	63
2025 Q4	$699K	Sell	1,759 -90,032	-98%	-$39.8M	﹤0.01%	870
2025 Q3	$41.9M	Sell	91,791 -531,324	-85%	-$216M	0.2%	142
2025 Q2	$203M	Buy	623,115 +466,651	+298%	+$129M	1.07%	6
2025 Q1	$42.2M	Buy	+156,464	New	+$40.2M	0.27%	111
2023 Q1	–	Sell	-95,068	Closed	-$22.6M	–	626
2022 Q4	$22.6M	Buy	+95,068	New	+$20.3M	0.3%	89

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Woodline Partners's ALNY Position: Q2 2026 in Review

Woodline Partners increased its Alnylam Pharmaceuticals (ALNY) stake by 0.98% in Q2 2026, buying an estimated $724K and bringing the position to 246,282 shares worth $74.1M. The position accounts for 0.23% of the portfolio, ranked #106.

Woodline Partners first reported a position in ALNY in Q4 2022 and has held it in 7 quarters since. The position peaked at $203M in Q2 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Woodline Partners held 246,282 shares of Alnylam Pharmaceuticals worth $74.1M as of Q2 2026.
Woodline Partners bought 2,399 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $724K.
Alnylam Pharmaceuticals made up 0.23% of Woodline Partners's portfolio in Q2 2026, its #106 holding.
Woodline Partners first reported a position in Alnylam Pharmaceuticals in Q4 2022 and has held it in 7 quarters since.
Woodline Partners's Alnylam Pharmaceuticals position peaked at $203M in Q2 2025.
790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.